Boston Scientific (BSX) Tests Critical Support Levels Following 33% Decline

Boston Scientific (BSX) is currently facing a critical technical juncture after its stock price plummeted nearly 33% from its previous peak. The stock is testing long-term support levels that have not been revisited in over a year, drawing significant attention from technical analysts. Market participants have identified the $71.88 level as a pivotal support point that will likely dictate the stock's near-term trajectory. A successful hold above this threshold could trigger a relief rally, whereas a decisive break below it might accelerate the current bearish trend. This development comes as equity traders in the healthcare sector evaluate whether the recent sell-off has reached an exhaustion point. The outcome of this support test is expected to provide clarity on whether BSX can stabilize or if further downside pressure is imminent.